Bayesian adaptive randomization trial of intravenous ketamine for veterans with late-life, treatment-resistant depression.
Contemporary clinical trials communications December 1, 2019 Brittany O'Brien, Charles E. Green, Rayan K. Al Jurdi et al. 10 citations
More than eleven million U.S. Veterans are at least 65 years of age, an age group of which almost 20% suffers from clinically significant depressive symptoms. Available pharmacological treatments are suboptimal for patients, including veterans, with late-life depression. Ketamine has emerged as a potentially promising rapid-acting therapy for treatment-resistant depression (TRD). However, few...